MedTrace Logo

National Registry of rFVIIa (Novoseven) in Haemorrhagic Traumatology

NCT01532661 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 114

Last updated 2014-11-18

No results posted yet for this study

Summary

The rFVIIa (Novoseven) has been tested in traumatic hemorrhage but its efficiency has not been proven yet in this context. A national register has been set up in France identifying the patients which received rFVIIa.

Those patients had persistent and active bleeding after severe trauma despite surgery and/or interventional radiology embolization.

The aim of this present study is to report the first clinical results in those situations of patients treated with rFVIIa.

Conditions

Interventions

OTHER

observational study

data collected by investigators

Sponsors & Collaborators

  • Novo Nordisk A/S

    collaborator INDUSTRY

  • Société Française d'Anesthésie et de Réanimation

    collaborator OTHER

  • University Hospital, Grenoble

    lead OTHER

Principal Investigators

  • PAYEN JF, MD · University Hospital, Grenoble

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2012-09-30
Completion
2012-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01532661 on ClinicalTrials.gov